Evidence map›Paper›PMID 29668328›Full record

ArticleCanadian journal of psychiatry. Revue canadienne de psychiatrie2018

Use of Placebo in Clinical Trials of Psychotropic Medication.

Mehrul Hasnain, Abraham Rudnick, Weldon S Bonnell, Gary Remington, Raymond W Lam

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mehrul Hasnain1 Associate Professor, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland.
Abraham Rudnick2 Professor, Section of Psychiatry, Northern Ontario School of Medicine, Lakehead and Laurentian Universities, Thunder Bay and Sudbury, Ontario; Vice-President and Chief of Psychiatry, Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario; Chief Scientist, Thunder Bay Regional Health Research Institute, Thunder Bay, Ontario.
Weldon S Bonnell3 Associate Professor, Discipline of Psychiatry, Memorial University of Newfoundland, St. John's, Newfoundland.
Gary Remington4 Professor, Departments of Psychiatry and Psychological Clinical Science, Faculty of Medicine, University of Toronto; Chief, Schizophrenia Division, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario.
Raymond W Lam5 Professor and BC Leadership Chair in Depression Research, Department of Psychiatry, University of British Columbia; Director, Mood Disorders Centre, Djavad Mowafaghian Centre for Brain Health, Vancouver, British Columbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This position paper has been substantially revised by the Canadian Psychiatric Association's Research Committee and approved for republication by the CPA's Board of Directors on March 31, 2017. The original position paper

Indexed as

PlacebosPsychotropic DrugsResearch DesignCanadaClinical Trials as TopicHumansMental DisordersPsychiatrySocieties, MedicalPlacebosPsychotropic Drugs

Identifiers

PMID29668328
PMCPMC5912304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.